Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Induction Chemotherapy"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 21-40 z 6059
Tytuł:
Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure.
Autorzy:
Yang XL; Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, 510060, Guangzhou, People's Republic of China.
Zhang LL; Department of Molecular Diagnostics, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China.
Kou J; Department of Anaesthesiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China.
Zhou GQ; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Centre of Cancer Medicine, Sun Yat-sen University Cancer Centre, 651 Dongfeng Road East, 510060, Guangzhou, People's Republic of China.
Wu CF; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Centre of Cancer Medicine, Sun Yat-sen University Cancer Centre, 651 Dongfeng Road East, 510060, Guangzhou, People's Republic of China.
Sun Y; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Centre of Cancer Medicine, Sun Yat-sen University Cancer Centre, 651 Dongfeng Road East, 510060, Guangzhou, People's Republic of China. .
Lin L; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Centre of Cancer Medicine, Sun Yat-sen University Cancer Centre, 651 Dongfeng Road East, 510060, Guangzhou, People's Republic of China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Nov 29; Vol. 22 (1), pp. 1230. Date of Electronic Publication: 2022 Nov 29.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/radiotherapy
Humans ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/radiotherapy ; Cisplatin/therapeutic use ; Chemoradiotherapy ; Treatment Failure
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early changes in gene expression profiles in AML patients during induction chemotherapy.
Autorzy:
Jakobsen I; Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.; Department of Laboratory Medicine, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Sundkvist M; Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Björn N; Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Gréen H; Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.; Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden.
Lotfi K; Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. .; Department of Hematology, Linköping University Hospital, 581 85, Linköping, Sweden. .
Pokaż więcej
Źródło:
BMC genomics [BMC Genomics] 2022 Nov 14; Vol. 23 (1), pp. 752. Date of Electronic Publication: 2022 Nov 14.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; NF-kappa B/genetics ; Transcriptome ; Pilot Projects ; Cytarabine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy.
Autorzy:
Hung CJ; Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, No.386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung City, 81362, Taiwan (R.O.C.).
Kang BH; Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, No.386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung City, 81362, Taiwan (R.O.C.).; Department of Pharmacy, Tajen University, Pingtung, Taiwan.; School of Medicine, National Defense Medical Center, Taipei, Taiwan.; Department of Otolaryngology, Head and Neck Surgery, Tri-Service General Hospital, Taipei, Taiwan.
Chang KM; Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, No.386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung City, 81362, Taiwan (R.O.C.).
Kang YY; Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.; Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yin CH; Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Lee CC; Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, No.386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung City, 81362, Taiwan (R.O.C.). .; School of Medicine, National Defense Medical Center, Taipei, Taiwan. .; Department of Otolaryngology, Head and Neck Surgery, Tri-Service General Hospital, Taipei, Taiwan. .; Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University, Taipei, Taiwan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Oct 21; Vol. 22 (1), pp. 1084. Date of Electronic Publication: 2022 Oct 21.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Head and Neck Neoplasms*/drug therapy
Humans ; Male ; Platinum ; Docetaxel/adverse effects ; Alanine Transaminase ; Retrospective Studies ; Body Composition
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Study of Peripheral Blood Parameters to Predict Response to Induction Chemotherapy and Overall Survival in Advanced Laryngeal Squamous Cell Carcinoma.
Autorzy:
Xu J; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Yang Y; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Zhong Q; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Hou L; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Ma H; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Zhang Y; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Feng L; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
He S; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Lian M; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Fang J; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Wang R; Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Sep 09; Vol. 29 (9), pp. 6472-6484. Date of Electronic Publication: 2022 Sep 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Induction Chemotherapy*
Laryngeal Neoplasms*/drug therapy
Squamous Cell Carcinoma of Head and Neck*/drug therapy
Albumins/therapeutic use ; Cholesterol/therapeutic use ; Fibrinogen/therapeutic use ; Hemoglobins/therapeutic use ; Humans ; Lipoproteins, HDL/therapeutic use ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.
Autorzy:
Lin W; Department of Hematology, The First Hospital of Putian City, Putian, People's Republic of China.
Chen X; Department of Hematology, The First Hospital of Putian City, Putian, People's Republic of China.
Zheng H; Department of Hematology, The First Hospital of Putian City, Putian, People's Republic of China.
Cai Z; Department of Hematology, The First Hospital of Putian City, Putian, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2231741.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*
Humans ; Bortezomib/therapeutic use ; Induction Chemotherapy ; Prognosis ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cell Cycle ; Treatment Outcome ; Dexamethasone/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
Autorzy:
Zhong K; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. .
Shi Y; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Gao Y; Department of Hematology, Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province), Shijiazhuang, China.
Zhang H; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhang M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang Q; Department of Oncology, Shanxi Academy of Medical Sciences & Shanxi Bethune Hospital, Shanxi Bethune Hospital affiliated to Shanxi Medical University, Taiyuan, China.
Cen X; Department of Hematology, Peking University First Hospital, Beijing, China.
Xue M; Department of Hematology, Air Force Medical Center, Beijing, China.
Qin Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhao Y; Department of Hematology, the General Hospital of PLA, Beijing, China.
Zhang L; Department of Lymphoma, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liang R; Department of Hematology, Xijing Hospital, Air Force Military Medical University, Xi'an, China.
Wang N; Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China.
Xie Y; Departments of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China.
Yang Y; Department of Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China.
Liu A; Department of Hematology and Lymphoma, Cancer hospital of Harbin Medical University, Haerbin, China.
Bao H; Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China.
Wang J; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Cao B; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Zhang W; Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Zhang W; Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Aug 11; Vol. 23 (1), pp. 746. Date of Electronic Publication: 2023 Aug 11.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Central Nervous System Neoplasms*/pathology
Lymphoma*
Adult ; Humans ; Methotrexate/therapeutic use ; Teniposide/therapeutic use ; Induction Chemotherapy ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Central Nervous System
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma.
Autorzy:
Pei W; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China.
Wang C; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China.
Liao H; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China.
Chen X; Southern Medical University, Guangzhou, China.
Wei Y; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China.
Huang X; Department of Radiology, Wuzhou red cross hospital, Wuzhou, Guangxi, China.
Liang X; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China.
Bao H; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China.
Su D; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China. .
Jin G; Department of Medical Imaging Center, Guangxi Medical University Cancer Hospital, No. 71, Hedi Rd, Nanning, 530021, Guangxi, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Jul 06; Vol. 22 (1), pp. 739. Date of Electronic Publication: 2022 Jul 06.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*/methods
Nasopharyngeal Neoplasms*/diagnostic imaging
Nasopharyngeal Neoplasms*/drug therapy
Chemoradiotherapy/methods ; Humans ; Magnetic Resonance Imaging/methods ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/therapy ; Progression-Free Survival
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients.
Autorzy:
Bi Y; Shandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.; Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
Wang Z; Department of Hematology, Haici Medical Group Qingdao, Qingdao, Shandong, China.
Feng S; Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
Wang Y; Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
Zhao Y; Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
Li H; Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
Yu J; Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
Liu Q; Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
Zhu C; Shandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. .; Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China. .
Li M; Center for Big Data Research in Health and Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 May 01; Vol. 22 (1), pp. 477. Date of Electronic Publication: 2022 May 01.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Blood Cell Count ; Humans ; Platelet Count ; Remission Induction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Autorzy:
Tao HY; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Zhan ZJ; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Qiu WZ; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Liao K; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Yuan YW; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Zheng RH; Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong, P.R. China.
Pokaż więcej
Źródło:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Apr; Vol. 18 (2), pp. e111-e118. Date of Electronic Publication: 2021 May 04.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoradiotherapy ; Cisplatin ; Docetaxel ; Fluorouracil/adverse effects ; Humans ; Nasopharyngeal Carcinoma/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Propensity Score ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study.
Autorzy:
Zhou Y; Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Guizhou, China.; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Lu T; Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Guizhou, China.
Li Y; School of Public Health, Zunyi Medical University, Guizhou, China.
Qin Y; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Lu Y; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Tian Q; Division of Infectious Diseases, the Third People's Hospital of Guilin, Guangxi, China.
Lan K; Division of Infectious Disease, Longtan Hospital of Guangxi Zhuang Autonomous Region, Guangxi, China.
Zhou G; Division of Infectious Diseases, the First Hospital of Changsha, Hunan, China.
Qin Y; Division of Infectious Diseases, the Fourth People's Hospital of Nanning, Guangxi, China.
Harypursat V; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Li S; Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Guangxi, China.
Lin S; Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Guizhou, China. .; College of Laboratory Medicine, Zunyi Medical University, Zunyi, China. .
Chen Y; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China. .; School of Public Health, Zunyi Medical University, Guizhou, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Oct 20; Vol. 23 (1), pp. 707. Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Anemia*/chemically induced
Anemia*/drug therapy
Leukopenia*/chemically induced
Leukopenia*/drug therapy
HIV Infections*/complications
HIV Infections*/drug therapy
Thrombocytopenia*/chemically induced
Thrombocytopenia*/drug therapy
Humans ; Amphotericin B/adverse effects ; Antifungal Agents/therapeutic use ; Prospective Studies ; Induction Chemotherapy
SCR Disease Name:
talaromycosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bortezomib-based induction therapy followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients: A single-center experience and review of Indian literature.
Autorzy:
Kathrotiya M; Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Radhakrishnan V; Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Bhave SJ; Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Nag A; Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Arora N; Laboratory Hematology and Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India.
Roychoudhry M; Department of Clinical Hematology and HCT, Nursing Division, Tata Medical Center, Kolkata, West Bengal, India.
Parihar M; Laboratory Hematology and Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India.
Mishra D; Laboratory Hematology and Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India.
Nair R; Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Chandy M; Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Kumar J; Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Pokaż więcej
Źródło:
Indian journal of cancer [Indian J Cancer] 2023 Oct 01; Vol. 60 (4), pp. 486-492. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Humans ; Bortezomib/therapeutic use ; Induction Chemotherapy ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
MCQs on Bortezomib-based induction therapy followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients: A single-center experience and review of Indian literature.
Autorzy:
Dsouza H; Medical Oncologist, Grace Oncology Centre, Vasai, Maharashtra, India.
Pokaż więcej
Źródło:
Indian journal of cancer [Indian J Cancer] 2023 Oct 01; Vol. 60 (4), pp. 570-571. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Bortezomib/therapeutic use ; Induction Chemotherapy ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Urine biomarker score captures response to induction therapy with lupus nephritis.
Autorzy:
Cody EM; Division of Nephrology, Hypertension and Pheresis, Department of Pediatrics, Washington University in St. Louis School of Medicine, 660 S. Euclid Ave, Campus, Box 8116, St. Louis, MO, 63110, USA. .
Wenderfer SE; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.; Nephrology, B.C. Children's Hospital, Vancouver, BC, Canada.
Sullivan KE; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Kim AHJ; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Figg W; Medical School, Baylor College of Medicine, Houston, TX, USA.
Ghumman H; Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Qiu T; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Huang B; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Devarajan P; Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
Brunner HI; Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.; Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
Pokaż więcej
Źródło:
Pediatric nephrology (Berlin, Germany) [Pediatr Nephrol] 2023 Aug; Vol. 38 (8), pp. 2679-2688. Date of Electronic Publication: 2023 Jan 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Lupus Nephritis*/diagnosis
Lupus Nephritis*/drug therapy
Lupus Nephritis*/pathology
Lupus Erythematosus, Systemic*
Young Adult ; Humans ; Child ; Induction Chemotherapy ; Case-Control Studies ; Biomarkers ; Kidney/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Postoperative bronchopleural fistula after induction therapy with bevacizumab.
Autorzy:
Wada H; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.; Department of Thoracic Surgery, International University Health and Welfare School of Medicine, Narita, Japan.
Suzuki H; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Tanaka K; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Sakairi Y; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Yoshino I; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Aug; Vol. 14 (22), pp. 2229-2232. Date of Electronic Publication: 2023 Jun 20.
Typ publikacji:
Case Reports
MeSH Terms:
Bronchial Fistula*/etiology
Pleural Diseases*/etiology
Pleural Diseases*/surgery
Lung Neoplasms*/drug therapy
Lung Neoplasms*/surgery
Lung Neoplasms*/complications
Male ; Humans ; Aged ; Bevacizumab/adverse effects ; Induction Chemotherapy ; Pneumonectomy/adverse effects ; Bronchi ; Postoperative Complications/drug therapy ; Postoperative Complications/etiology ; Postoperative Complications/surgery
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Induction chemotherapy-based organ-preservation protocol improve the function preservation compared with immediate total laryngectomy for locally advanced hypopharyngeal cancer-Results of a matched-pair analysis.
Autorzy:
Yang Y; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Feng L; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Zhong Q; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Zhang Y; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Huang Z; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Zhang S; Department of Oncology, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.
Li S; Department of Radiology, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.
Gao J; Department of Radiotherapy, Seventh Medical Center, General Hospital of the Chinese People's Liberation Army, Beijing, China.
Hou L; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Ma H; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
He S; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Shi Q; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Lian M; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Zhao Y; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Shen X; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Chen J; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Wang L; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Li H; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Chen S; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Xu J; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Wang R; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Fang J; Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China.; Key Laboratory of Otorhinolaryngology, Head and Neck Surgery, Beijing Institute of Otorhinolaryngology, Beijing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 17078-17086. Date of Electronic Publication: 2023 Jul 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hypopharyngeal Neoplasms*/drug therapy
Hypopharyngeal Neoplasms*/surgery
Laryngeal Neoplasms*/drug therapy
Laryngeal Neoplasms*/surgery
Head and Neck Neoplasms*/pathology
Humans ; Laryngectomy/methods ; Induction Chemotherapy/methods ; Matched-Pair Analysis ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy.
Autorzy:
Halpern AB; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Howard NP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hendrie PC; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Percival MM; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hartley GA; Pfizer Inc, New York, NY, USA.
Welch VL; Pfizer Inc, New York, NY, USA.
Estey EH; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Walter RB; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Jan; Vol. 63 (1), pp. 142-151. Date of Electronic Publication: 2021 Oct 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Induction Chemotherapy*/adverse effects
Leukemia, Myeloid, Acute*/complications
Leukemia, Myeloid, Acute*/drug therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Inpatients ; Outpatients ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
Autorzy:
Zheng H; Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Zhou P; Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Wang J; Department of Head and Neck Oncology, Department of Radiation Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Yu YF; Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Zhou R; Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Lin Q; Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Wu SG; Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Jul; Vol. 12 (14), pp. 14979-14987. Date of Electronic Publication: 2023 May 22.
Typ publikacji:
Journal Article
MeSH Terms:
Epstein-Barr Virus Infections*/pathology
Nasopharyngeal Neoplasms*/pathology
Humans ; Nasopharyngeal Carcinoma/pathology ; DNA, Viral/genetics ; Induction Chemotherapy ; Herpesvirus 4, Human/genetics ; Neoplasm Recurrence, Local/drug therapy ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy.
Autorzy:
He S; Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Wu YL; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Gao Y; Department of Data Mining and Analysis, Guangzhou Tianpeng Technology Co., Ltd, Guangzhou, China.
He D; Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Huang Y; Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 May; Vol. 12 (9), pp. 10536-10552. Date of Electronic Publication: 2023 Apr 16.
Typ publikacji:
Journal Article
MeSH Terms:
Nasopharyngeal Neoplasms*/radiotherapy
Humans ; Aged ; Middle Aged ; Nasopharyngeal Carcinoma/pathology ; Induction Chemotherapy/adverse effects ; Chemoradiotherapy/methods ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Risk Assessment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Percent change in apparent diffusion coefficient and plasma EBV DNA after induction chemotherapy identifies distinct prognostic response phenotypes in advanced nasopharyngeal carcinoma.
Autorzy:
Liu LT; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Guo SS; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Li H; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Imaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Lin C; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Sun R; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Chen QY; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Liang YJ; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Tang QN; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Sun XS; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Tang LQ; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
Xie CM; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Imaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Mai HQ; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. .; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Dec 09; Vol. 21 (1), pp. 1320. Date of Electronic Publication: 2021 Dec 09.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Nasopharyngeal Carcinoma*/diagnostic imaging
Nasopharyngeal Carcinoma*/drug therapy
Nasopharyngeal Carcinoma*/epidemiology
Nasopharyngeal Carcinoma*/pathology
DNA, Viral/*blood
Herpesvirus 4, Human/*genetics
Adolescent ; Adult ; Aged ; Diffusion Magnetic Resonance Imaging ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 21-40 z 6059

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies